1
|
Shimizu R, Suda K, Takemoto T, Fukuda S, Chiba M, Shimoji M, Soh J, Mitsudomi T, Tsutani Y. A case of late-onset bleeding from an intercostal artery pseudoaneurysm after hemostasis using soft coagulation. Surg Case Rep 2024; 10:49. [PMID: 38416260 PMCID: PMC10899919 DOI: 10.1186/s40792-024-01851-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 02/21/2024] [Indexed: 02/29/2024] Open
Abstract
BACKGROUND The use of soft coagulation is becoming common in thoracic surgery. Soft coagulation provides rapid hemostasis from small vessels during surgery by dehydrating tissue and denaturing proteins, without burning the tissue. CASE PRESENTATION A 68-year-old man, with a history of right lower lobectomy 3 years prior, underwent a partial resection of the right upper lobe for a pulmonary nodule suspicious for secondary lung cancer. During the surgery, dissection of the adhesion caused a bleeding from the 6th intercostal artery, and hemostasis was achieved using soft coagulation (some degree of tissue carbonization was noticed at later mortality and morbidity conference). He experienced hemoptysis at postoperative day 18 and was transferred to our hospital. Contrast-enhanced CT scan revealed bleeding from the pseudoaneurysm of the 6th intercostal artery. Embolization was performed by angiography to stop the bleeding. CONCLUSIONS We experienced a case of late-onset bleeding from a pseudoaneurysm related to soft coagulation hemostasis. Lessons learned from this patient are that additional hemostasis, such as ligation, would be considered for small arteries after hemostasis has been achieved by soft coagulation, especially when some degree of tissue carbonization is suspected.
Collapse
Affiliation(s)
- Rie Shimizu
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Kenichi Suda
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan.
| | - Toshiki Takemoto
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Shota Fukuda
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Masato Chiba
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Masaki Shimoji
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Junichi Soh
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Tetsuya Mitsudomi
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| | - Yasuhiro Tsutani
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8581, Japan
| |
Collapse
|
2
|
Wang Y, Li J, Wu Q, Chang Q, Guo S. Pathogen distribution in pulmonary infection in chinese patients with lung cancer: a systematic review and meta-analysis. BMC Pulm Med 2023; 23:402. [PMID: 37872568 PMCID: PMC10594703 DOI: 10.1186/s12890-023-02681-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 09/27/2023] [Indexed: 10/25/2023] Open
Abstract
BACKGROUND The immunity of patients with lung cancer decreases after treatment; thus, they are easily infected with pathogenic bacteria that causes pulmonary infections. Understanding the distribution characteristics of pathogenic bacteria in pulmonary infection in patients with lung cancer after treatment can provide a basis to effectively prevent infection and rationally use antibacterial drugs. However, no meta-analyses have assessed the distribution characteristics of pathogenic bacteria in mainland China. Therefore, our meta-analysis aimed to investigate the pathogen distribution in pulmonary infection in Chinese patients with lung cancer. METHODS A literature search was conducted to study the pathogen distribution in pulmonary infection in Chinese patients with lung cancer between January 1, 2020 and December 31, 2022, using English and Chinese databases. The relevant data were extracted. The meta-analysis was performed using a random-effects model ( I2 > 50%) with 95% confidence intervals for forest plots. Data were processed using RevMan 5.3. RESULTS Fifteen studies (2,683 strains in 2,129 patients with pulmonary infection were cultured) met the evaluation criteria. The results showed that Gram-negative bacteria had the highest detection rate (63%), followed by Gram-positive bacteria (23%), and fungi (12%). Among the Gram-negative bacteria detected, the distribution of the main pathogenic bacteria was Klebsiella pneumonia (17%), Pseudomonas aeruginosa (14%), Escherichia coli (13%), Acinetobacter baumannii (7%), Enterobacter cloacae (4%), and Hemophilus influenza (4%). Moreover, the prevalence of pulmonary infections after chemotherapy (53%) was significantly higher than that after surgery (10%), P < 0.05. CONCLUSIONS The prevalence of pulmonary infections after treatment, especially after chemotherapy, is high in Chinese patients with lung cancer, and Gram-negative bacteria are the predominant pathogens. Further studies are needed to monitor the prevalence of pulmonary infections and pathogen distribution in lung cancer patients in mainland China.
Collapse
Affiliation(s)
- Yanyan Wang
- Department of Respiratory and Critical Care Medicine, Linfen Central Hospital, 041000, Linfen, China
| | - Jia Li
- Department of Respiratory and Critical Care Medicine, Linfen Central Hospital, 041000, Linfen, China
| | - Qinqin Wu
- Department of Respiratory and Critical Care Medicine, Linfen Central Hospital, 041000, Linfen, China
| | - Qin Chang
- Department of Respiratory and Critical Care Medicine, Linfen Central Hospital, 041000, Linfen, China
| | - Shuming Guo
- Department of Respiratory and Critical Care Medicine, Linfen Central Hospital, 041000, Linfen, China.
| |
Collapse
|
3
|
Motas N, Manolache V, Scarci M, Nimigean V, Nimigean VR, Simion L, Mizea MC, Trifanescu OG, Galateanu B, Gherghe M, Capsa CM, Gonzalez-Rivas D, Davidescu MD. Salvage Surgery for Small-Cell Lung Cancer-A Literature Review. Cancers (Basel) 2023; 15:cancers15082241. [PMID: 37190169 DOI: 10.3390/cancers15082241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 04/03/2023] [Accepted: 04/05/2023] [Indexed: 05/17/2023] Open
Abstract
(1) Background: Salvation surgery for small-cell lung cancer (SCLC) is exceptionally performed, and only a few cases are published. (2) Methods: There are 6 publications that present 17 cases of salvation surgery for SCLC-the salvation surgery was performed in the context of modern clearly established protocols for SCLC and after including SCLC in the TNM (tumor, node, metastasis) staging in 2010. (3) Results: After a median follow-up of 29 months, the estimated overall survival (OS) was 86 months. The median estimated 2-year survival was 92%, and the median estimated 5-year survival was 66%. (4) Conclusion: Salvage surgery for SCLC is a relatively new and extremely uncommon concept and represents an alternative to second-line chemotherapy. It is valuable because it may offer a reasonable treatment for selected patients, good local control, and a favorable survival outcome.
Collapse
Affiliation(s)
- Natalia Motas
- Discipline of Thoracic Surgery, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania
- Department of Thoracic Surgery, "Prof. Dr. Al. Trestioreanu" Institute of Oncology, 022328 Bucharest, Romania
- Department of Thoracic Surgery, Oncology Hospital Memorial, 013812 Bucharest, Romania
| | - Veronica Manolache
- Discipline of Thoracic Surgery, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania
- Department of Thoracic Surgery, Oncology Hospital Memorial, 013812 Bucharest, Romania
| | - Marco Scarci
- Department of Thoracic Surgery, Imperial College NHS Healthcare, Hammersmith Hospital Du Cane Road, London W12 0HS, UK
| | - Victor Nimigean
- Department of Anatomy, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy in Bucharest, 022328 Bucharest, Romania
| | - Vanda Roxana Nimigean
- Department of Oral Rehabilitation, Faculty of Dentistry, "Carol Davila" University of Medicine and Pharmacy in Bucharest, 022328 Bucharest, Romania
| | - Laurentiu Simion
- Discipline of General and Oncological Surgery, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania
- Department of General and Oncologic Surgery, "Prof. Dr. Al. Trestioreanu" Institute of Oncology, 022328 Bucharest, Romania
| | - Madalina Cristiana Mizea
- Discipline of Thoracic Surgery, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania
- Department of Thoracic Surgery, "Prof. Dr. Al. Trestioreanu" Institute of Oncology, 022328 Bucharest, Romania
| | - Oana Gabriela Trifanescu
- Discipline of Oncology, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania
- Department of Radiotherapy, "Prof. Dr. Al. Trestioreanu" Institute of Oncology, 022328 Bucharest, Romania
| | - Bianca Galateanu
- Department of Biochemistry and Molecular Biology, University of Bucharest, 022328 Bucharest, Romania
| | - Mirela Gherghe
- Discipline of Nuclear Medicine, "Prof. Dr. Al. Trestioreanu" Institute of Oncology and University Emergency Military Hospital "Dr. Carol Davila", 022328 Bucharest, Romania
| | - Cristina Mirela Capsa
- Department of Radiology "Prof. Dr. Alexandru Trestioreanu", 022328 Bucharest, Romania
| | - Diego Gonzalez-Rivas
- Department of Thoracic Surgery, Oncology Hospital Memorial, 013812 Bucharest, Romania
- Department of Thoracic Surgery and Minimally Invasive Thoracic Surgery Unit (UCTMI), Coruña University Hospital, 15008 Coruña, Spain
| | - Mihnea Dan Davidescu
- Discipline of Thoracic Surgery, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania
- Department of Thoracic Surgery, "Prof. Dr. Al. Trestioreanu" Institute of Oncology, 022328 Bucharest, Romania
| |
Collapse
|
4
|
Nagano T, Tachihara M, Nishimura Y. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Curr Cancer Drug Targets 2020; 19:595-630. [PMID: 30526458 DOI: 10.2174/1568009619666181210114559] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 11/21/2018] [Accepted: 11/28/2018] [Indexed: 12/21/2022]
Abstract
Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, gefitinib, which was the first molecular targeted therapeutic agent, has actually doubled the survival time of NSCLC patients. Vigorous efforts of clinicians and researchers have revealed that lung cancer develops through the activating mutations of many driver genes including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), v-Raf murine sarcoma viral oncogene homolog B (BRAF), and rearranged during transfection (RET) genes. Although ALK, ROS1, and RET are rare genetic abnormalities, corresponding tyrosine kinase inhibitors (TKIs) can exert dramatic therapeutic effects. In addition to anticancer drugs targeting driver genes, bevacizumab specifically binds to human vascular endothelial growth factor (VEGF) and blocks the VEGF signaling pathway. The VEGF signal blockade suppresses angiogenesis in tumor tissues and inhibits tumor growth. In this review, we also explore immunotherapy, which is a promising new NSCLC treatment approach. In general, antitumor immune responses are suppressed in cancer patients, and cancer cells escape from the immune surveillance mechanism. Immune checkpoint inhibitors (ICIs) are antibodies that target the primary escape mechanisms, immune checkpoints. Patients who respond to ICIs are reported to experience longlasting therapeutic effects. A wide range of clinical approaches, including combination therapy involving chemotherapy or radiation plus adjuvant therapy, are being developed.
Collapse
Affiliation(s)
- Tatsuya Nagano
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Motoko Tachihara
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yoshihiro Nishimura
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
5
|
Song GQ, Li GG, Chen F, Chen DS, Qian HJ, Deng XE, Lu HQ, Lin B. Radiofrequency ablation for lung squamous cell carcinoma in a single-lung patient: A case report and literature review. Medicine (Baltimore) 2019; 98:e15805. [PMID: 31169680 PMCID: PMC6571389 DOI: 10.1097/md.0000000000015805] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
RATIONALE High morbidity and high mortality are the main features of non-small cell lung cancer (NSCLC). Radiofrequency ablation, which produces a large amount of heat to kill tumor cells, is one effective way to treat this disease. PATIENT CONCERNS We report the case of a 74-year-old man who presented with a 1-month history of right chest pain. His left lung was removed 12 years prior. Chest computed tomography (CT) revealed a mass in the right lower lobe. DIAGNOSES An excision biopsy of the mass showed lung squamous cell carcinoma. INTERVENTIONS We performed radiofrequency ablation. OUTCOMES The patient underwent 3.5 and 10 months of follow-up, with a partial response and complete remission, respectively. LESSONS CT-guided radiofrequency ablation is a safe and an effective minimally invasive treatment option. Radiofrequency appears to be a valuable alternative to surgery for inoperable patients presenting with a single-lung NSCLC.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Bin Lin
- Department of Pharmacy, Changxing People's Hospital, Huzhou, P.R. China
| |
Collapse
|
6
|
Osarogiagbon RU, Veronesi G, Fang W, Ekman S, Suda K, Aerts JG, Donington J. Early-Stage NSCLC: Advances in Thoracic Oncology 2018. J Thorac Oncol 2019; 14:968-978. [PMID: 30851441 PMCID: PMC6534444 DOI: 10.1016/j.jtho.2019.02.029] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Revised: 02/22/2019] [Accepted: 02/24/2019] [Indexed: 12/21/2022]
Abstract
2018 was a banner year for all thoracic oncology, but especially for early-stage NSCLC. Three seminal events occurred in the approximately 18 months from mid-2017 to the end of 2018: in June 2017 at the American Society of Clinical Oncology Annual Meeting a small, relatively unheralded study from Max Diehn's group at Stanford University reported on the use of a novel "cancer personalized profiling by deep sequencing" circulating tumor-DNA technology to identify minimal residual disease in patients after curative-intent radiation or surgery for NSCLC; in April 2018 at the American Association for Cancer Research Annual Meeting, Drew Pardoll presented a small pilot study of 21 patients who had received two doses of preoperative nivolumab; in September 2018, at the 19th World Conference on Lung Cancer, Harry J. De Koning presented the long-awaited results of the Dutch-Belgian Lung Cancer Screening Trial (NELSON). These three seminal studies, along with others which are reviewed in this paper, promise to accelerate our progress towards a world in which lung cancer is identified early, more patients undergo curative-intent treatment that achieves the promised cure, and those at risk for failure after treatment are identified early, when the cancer remains most vulnerable. The day is around the corner when lung cancer is defanged and no longer the worldwide terror it currently is. We herein present an overview of the most recent body of work that moves us inexorably towards that day.
Collapse
Affiliation(s)
| | - Giulia Veronesi
- Division of Thoracic and General Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - Wentao Fang
- Department of Thoracic Surgery, Shanghai Chest Hospital, Jiaotong University Medical School, Shanghai, China
| | - Simon Ekman
- Thoracic Oncology Center, Karolinska University Hospital/Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Kenichi Suda
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - Joachim G Aerts
- Thoracic Oncology Department, Erasumus University Medical Center, Rotterdam, Netherlands
| | - Jessica Donington
- Section of Thoracic Surgery, University of Chicago, Chicago, Illinois
| |
Collapse
|
7
|
Opitz I, Schneiter D. [Modern Aspects of Lung Cancer Surgery]. PRAXIS 2018; 107:1383-1391. [PMID: 31166876 DOI: 10.1024/1661-8157/a003141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Modern Aspects of Lung Cancer Surgery Abstract. Surgery is still an inherent part of the treatment of non-small cell lung cancer. This article summarizes various aspects of the surgical treatment of early and locally advanced stages of lung cancer. Minimally invasive techniques for lung cancer resection - video- or robotic-assisted - are today standard for early stages. Perioperative mortality is below 1 % and the oncological outcome is equal to open surgery. The learning curve is at 50 VATS lobectomies in a program with a minimum of 25 VATS lobectomies/year to obtain satisfying results. In specialized centers, Locally advanced tumors can be resected technically and oncologically safe, with acceptable morbidity and mortality rates. With careful patient selection and planning, 5-year survival rates can be as high as 48 %.
Collapse
|
8
|
Fei QL, Zhou YY, Yuan YX, Sun SQ. An applied anatomical study of bronchial artery. Surg Radiol Anat 2017; 40:55-61. [PMID: 28942519 DOI: 10.1007/s00276-017-1918-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 08/31/2017] [Indexed: 12/28/2022]
Abstract
The aim of this study was to reveal the external features of the bronchial artery (BA) system, so as to provide morphological basis for clinic. The BAs in 48 adult cadavers were dissected and analyzed. The number of BAs in 48 cases was 118. The incidence of BA arising from thoracic aorta, right posterior intercostal artery, and right subclavian artery was 69.49, 27.12, and 3.39%, respectively. The origin of BAs in individual specimen might be single, two, or all of them, respectively. According to the different origin and/or origins of BAs, it could be divided into five categories. As for the course of BAs, in this study, all the left BAs arising from thoracic aorta passed forward around the left side of esophagus and then entered left pulmonary hilum; most (n = 15) of the right BAs arising from thoracic aorta passed forward around the left side of esophagus and then entered right pulmonary hilum; a few (n = 8) of the right BAs arising from thoracic passed forward the right side of esophagus and bronchus and then entered right pulmonary hilum. Besides, in our group, the special courses were that right intercostal-bronchial trunk (RICBT) arising from thoracic aorta passed between vertebra and esophagus and gave off BA which curved forward around the right side of esophagus and then entered right pulmonary hilum, common bronchial trunk (CBT) arising from thoracic aorta passed forward around the left side of esophagus laying anterior to bronchus or posterior to bronchus, then dividing into a left and a right BAs entering right and left pulmonary hilum, respectively. In 4 cadavers, the RICBT gave off the radiculomedullary artery and BA in turn, so radiculomedullary artery has the same origin with BA. Of all BAs, the mean diameter of right posterior intercostal artery, CBT, left BA, and right BA was 2.17 ± 0.84, 1.79 ± 0.57, 1.44 ± 0.50, and 1.39 ± 0.38 mm, respectively. The information gained from this study will be of value in clinic application.
Collapse
Affiliation(s)
- Qing-Lin Fei
- The Second College of Clinical Medicine, Chongqing Medical University, Chongqing, 400016, China
| | - Yuan-Yuan Zhou
- The Second College of Clinical Medicine, Chongqing Medical University, Chongqing, 400016, China
| | - Yi-Xiao Yuan
- The Second College of Clinical Medicine, Chongqing Medical University, Chongqing, 400016, China
| | - Shan-Quan Sun
- Human Gross Morphology Lab, National Class Preclinical Medicine Experimental Teaching Demonstration Center, Chongqing Medical University, Chongqing, 400016, China.
| |
Collapse
|
9
|
Lu X, Yang L, Chen J, Zhou J, Tang X, Zhu Y, Qiu H, Shen J. The action and mechanism of myrislignan on A549 cells in vitro and in vivo. J Nat Med 2016; 71:76-85. [PMID: 27491743 DOI: 10.1007/s11418-016-1029-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 07/17/2016] [Indexed: 12/19/2022]
Abstract
Myrislignan is a natural compound with little pharmacological study. In our investigation, we investigated the effect of myrislignan in the induction of apoptosis in A549 cells in vitro and in vivo. Myrislignan inhibited the proliferation of A549 cells in a dose- and time-dependent manner assayed by MTT. In addition, Hoechst flow cytometry showed that myrislignan significantly induced apoptosis and cell cycle arrest in A549 cells. The apoptosis and anti-cell proliferation was mediated by the activation of mitogen-activated protein kinase and the inhibition of epidermal growth factor receptor signal pathway, change of mitochondrial membrane potential, the releasing of c-Myc, the downregulation of the level of the anti-apoptotic protein Bcl-2, and the upregulation of the level of the pro-apoptotic protein Bax. In conclusion, those results reveal a potential mechanism for the anti-cancer effect of myrislignan on human lung cancer, while suggesting that myrislignan may be a promising compound for the treatment of lung cancer.
Collapse
Affiliation(s)
- XinGang Lu
- Department of Traditional Chinese Medicine, HuaDong Hospital, FuDan University, Shanghai, 200040, People's Republic of China
| | - Liu Yang
- Department of Tumor, BaoShan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, 201999, People's Republic of China
| | - JingXian Chen
- Department of Traditional Chinese Medicine, RuiJin Hospital, JiaoTong University School of Medicine, Shanghai, 200025, People's Republic of China
| | - JiAn Zhou
- Department of Pulmonary, HuaDong Hospital, FuDan University, Shanghai, 200040, People's Republic of China
| | - XiaoDan Tang
- Department of Pulmonary, HuaDong Hospital, FuDan University, Shanghai, 200040, People's Republic of China
| | - YingGang Zhu
- Department of Pulmonary, HuaDong Hospital, FuDan University, Shanghai, 200040, People's Republic of China
| | - HongFu Qiu
- Department of Traditional Chinese Medicine, HuaDong Hospital, FuDan University, Shanghai, 200040, People's Republic of China
| | - Jie Shen
- Department of Pharmacy, HuaDong Hospital, FuDan University, No. 221, West YanAn Rd, Shanghai, 200040, People's Republic of China.
| |
Collapse
|